GlassScriptPhysician profile
Jose Alvarez
NPI 1912013699
$2,211.80
in general payments reported to CMS, 2019-2025
29 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $171 · 2021: $79.81 · 2022: $427 · 2023: $388 · 2024: $270 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $62.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.07 |
| Education | $62.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $532.47 | 2022-2024 | Intellis Adaptivestim, Synchromedii, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $288.92 | 2019-2023 | Infinion 16, Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $218.67 | 2019-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $192.72 | 2019-2025 | Freestyle Libre 3 |
| Nevro Corp. | $109.10 | 2019-2024 | Senza |
| Vertiflex, INC. | $96.30 | 2019 | |
| Pfizer INC. | $95.73 | 2019-2020 | |
| Averitas Pharma INC. | $78.62 | 2023-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $59.84 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $39.94 | 2022 | |
| Abbvie INC. | $39.08 | 2022-2023 | Botox |
| Valinor Pharma, LLC | $38.83 | 2025 | Movantik |
| Mml US, INC. | $37.97 | 2025 | Reactiv8 |
| Protega Pharmaceutials INC | $36.47 | 2025 | Roxybond |
| Globus Medical, INC. | $34.68 | 2025 | Vyrsa V1, Senza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $32.60 | 2023 | |
| Scilex Pharmaceuticals INC. | $31.00 | 2019 | |
| Zimmer Biomet Holdings, INC. | $30.71 | 2022 | |
| Biotronik Nro, INC. | $28.13 | 2025 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.21 | 2019 | |
| Edwards Lifesciences Corporation | $24.00 | 2024 | Hemosphere |
| Relievant Medsystems, INC. | $23.22 | 2023 | Intracept |
| Fidia Pharma USA INC. | $19.88 | 2022 | |
| Medtronic USA, INC. | $19.44 | 2020 | |
| Daiichi Sankyo INC. | $18.32 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $17.11 | 2020 | |
| Merck Sharp & Dohme LLC | $16.52 | 2019 | |
| Horizon Therapeutics Plc | $15.21 | 2019 | |
| Lilly USA, LLC | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.